• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲乳腺癌钼靶筛查中的假阳性结果:文献复习和服务性筛查项目调查。

False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes.

机构信息

Department of Research, Cancer Registry of Norway, Box 5313 Majorstua, 0403 Oslo, Norway.

出版信息

J Med Screen. 2012;19 Suppl 1:57-66. doi: 10.1258/jms.2012.012083.

DOI:10.1258/jms.2012.012083
PMID:22972811
Abstract

OBJECTIVE

To estimate the cumulative risk of a false-positive screening result in European mammographic screening programmes, and examine the rates and procedures of further assessment.

METHODS

A literature review was conducted to identify studies of the cumulative risk of a false-positive result in European screening programmes (390,000 women). We then examined aggregate data, cross-sectional information about further assessment procedures among women with positive results in 20 mammographic screening programmes from 17 countries (1.7 million initial screens, 5.9 million subsequent screens), collected by the European Network for Information on Cancer project (EUNICE).

RESULTS

The estimated cumulative risk of a false-positive screening result in women aged 50-69 undergoing 10 biennial screening tests varied from 8% to 21% in the three studies examined (pooled estimate 19.7%). The cumulative risk of an invasive procedure with benign outcome ranged from 1.8% to 6.3% (pooled estimate 2.9%). The risk of undergoing surgical intervention with benign outcome was 0.9% (one study only). From the EUNICE project, the proportions of all screening examinations in the programmes resulting in needle biopsy were 2.2% and 1.1% for initial and subsequent screens, respectively, though the rates differed between countries; the corresponding rates of surgical interventions among women without breast cancer were 0.19% and 0.07%.

CONCLUSION

The specific investigative procedures following a recall should be considered when examining the cumulative risk of a false-positive screening result. Most women with a positive screening test undergo a non-invasive assessment procedure. Only a small proportion of recalled women undergo needle biopsy, and even fewer undergo surgical intervention.

摘要

目的

估计欧洲乳腺筛查计划中假阳性筛查结果的累积风险,并检查进一步评估的比率和程序。

方法

进行文献回顾,以确定欧洲筛查计划中假阳性结果累积风险的研究(390,000 名女性)。然后,我们检查了汇总数据,以及来自 17 个国家的 20 个乳腺筛查计划中阳性结果女性进一步评估程序的横断面信息(170 万例初始筛查,590 万例后续筛查),由欧洲癌症信息网络(EUNICE)收集。

结果

在接受 10 次双年度筛查测试的 50-69 岁女性中,三项研究中估计的假阳性筛查结果累积风险从 8%到 21%不等(汇总估计值为 19.7%)。良性结果的侵袭性程序的累积风险从 1.8%到 6.3%不等(汇总估计值为 2.9%)。良性结果行手术干预的风险为 0.9%(仅一项研究)。从 EUNICE 项目中,各计划中所有筛查检查导致活检的比例分别为初始和后续筛查的 2.2%和 1.1%,尽管各国之间的比率不同;在没有乳腺癌的女性中,相应的手术干预率分别为 0.19%和 0.07%。

结论

在检查假阳性筛查结果的累积风险时,应考虑召回后特定的调查程序。大多数接受阳性筛查试验的女性接受非侵入性评估程序。只有一小部分被召回的女性接受了活检,而接受手术干预的女性则更少。

相似文献

1
False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes.欧洲乳腺癌钼靶筛查中的假阳性结果:文献复习和服务性筛查项目调查。
J Med Screen. 2012;19 Suppl 1:57-66. doi: 10.1258/jms.2012.012083.
2
The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program.挪威乳腺癌筛查项目中假阳性召回的累积风险。
Cancer. 2004 Oct 1;101(7):1501-7. doi: 10.1002/cncr.20528.
3
Predicting the risk of a false-positive test for women following a mammography screening programme.预测乳腺钼靶筛查项目中女性假阳性检测的风险。
J Med Screen. 2007;14(2):94-7. doi: 10.1258/096914107781261891.
4
Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme.基于人群的乳腺癌筛查项目中累积假阳性召回率及其与参与者相关因素的关联。
J Epidemiol Community Health. 2006 Apr;60(4):316-21. doi: 10.1136/jech.2005.042119.
5
The cumulative risk of false-positive results in the Norwegian Breast Cancer Screening Program: updated results.挪威乳腺癌筛查计划中假阳性结果的累积风险:更新结果。
Cancer. 2013 Nov 15;119(22):3952-8. doi: 10.1002/cncr.28320. Epub 2013 Aug 20.
6
Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet.欧洲乳腺癌服务筛查结果的证据总结以及对收益和危害平衡表的初步评估。
J Med Screen. 2012;19 Suppl 1:5-13. doi: 10.1258/jms.2012.012077.
7
Participation behaviour following a false positive test in the Copenhagen mammography screening programme.哥本哈根乳腺X线筛查项目中假阳性检测后的参与行为。
Acta Oncol. 2008;47(4):550-5. doi: 10.1080/02841860801935483.
8
Minority report - false negative breast assessment in women recalled for suspicious screening mammography: imaging and pathological features, and associated delay in diagnosis.少数病例报告——因乳腺钼靶筛查可疑而被召回的女性中乳腺评估假阴性:影像学和病理特征以及相关诊断延迟
Breast Cancer Res Treat. 2007 Sep;105(1):37-43. doi: 10.1007/s10549-006-9425-3. Epub 2006 Nov 18.
9
Mammographic screening programmes in Europe: organization, coverage and participation.欧洲的乳腺 X 光筛查计划:组织、覆盖范围和参与情况。
J Med Screen. 2012;19 Suppl 1:72-82. doi: 10.1258/jms.2012.012085.
10
The cumulative risk of false-positive screening results across screening centres in the Norwegian Breast Cancer Screening Program.挪威乳腺癌筛查项目中各筛查中心假阳性筛查结果的累积风险。
Eur J Radiol. 2014 Sep;83(9):1639-44. doi: 10.1016/j.ejrad.2014.05.038. Epub 2014 Jun 5.

引用本文的文献

1
[Importance of parametric and molecular imaging for therapeutic management of breast cancer].[参数成像和分子成像在乳腺癌治疗管理中的重要性]
Radiologie (Heidelb). 2025 Mar;65(3):154-161. doi: 10.1007/s00117-024-01394-x. Epub 2024 Dec 6.
2
Budget impact analysis of introducing digital breast tomosynthesis in breast cancer screening in Italy.在意大利,引入数字乳腺断层合成技术进行乳腺癌筛查的预算影响分析。
Radiol Med. 2024 Sep;129(9):1288-1302. doi: 10.1007/s11547-024-01850-7. Epub 2024 Aug 20.
3
Epidemiology of Breast Cancer Mortality in Kazakhstan, trends and Geographic Distribution.
哈萨克斯坦乳腺癌死亡率的流行病学,趋势和地理分布。
Asian Pac J Cancer Prev. 2023 Oct 1;24(10):3361-3371. doi: 10.31557/APJCP.2023.24.10.3361.
4
Contrast-Enhanced Spectral Mammography in the Evaluation of Breast Microcalcifications: Controversies and Diagnostic Management.对比增强光谱乳腺摄影术在乳腺微钙化评估中的应用:争议与诊断管理
Healthcare (Basel). 2023 Feb 9;11(4):511. doi: 10.3390/healthcare11040511.
5
Breast Cancer Screening and Perceptions of Harm among Young Adults in Japan: Results of a Cross-Sectional Online Survey.日本青年中乳腺癌筛查和对危害的认知:一项横断面在线调查的结果。
Curr Oncol. 2023 Feb 8;30(2):2073-2087. doi: 10.3390/curroncol30020161.
6
Evolution of breast cancer incidence in young women in a French registry from 1990 to 2018: Towards a change in screening strategy?1990 年至 2018 年法国登记处年轻女性乳腺癌发病率的演变:筛查策略是否需要改变?
Breast Cancer Res. 2022 Dec 5;24(1):87. doi: 10.1186/s13058-022-01581-5.
7
Setting a research agenda in trans health: An expert assessment of priorities and issues by trans and nonbinary researchers.制定跨性别健康研究议程:跨性别和非二元性别研究人员对优先事项和问题的专家评估。
Int J Transgend Health. 2022 Mar 11;23(4):392-408. doi: 10.1080/26895269.2022.2044425. eCollection 2022.
8
Tensor-Based Learning for Detecting Abnormalities on Digital Mammograms.基于张量学习的数字化乳腺X线摄影异常检测
Diagnostics (Basel). 2022 Oct 1;12(10):2389. doi: 10.3390/diagnostics12102389.
9
BI-RADS-Based Classification of Mammographic Soft Tissue Opacities Using a Deep Convolutional Neural Network.基于乳腺影像报告和数据系统(BI-RADS),利用深度卷积神经网络对乳腺钼靶软组织不透光区进行分类
Diagnostics (Basel). 2022 Jun 28;12(7):1564. doi: 10.3390/diagnostics12071564.
10
Advances in breast cancer screening modalities and status of global screening programs.乳腺癌筛查方式的进展及全球筛查项目的现状。
Chronic Dis Transl Med. 2022 May 25;8(2):112-123. doi: 10.1002/cdt3.21. eCollection 2022 Jun.